Replimune Group reported a net loss of $57.1 million, or $0.54 per share, for the fiscal second quarter ended September 30, 2026, compared to an $83.1 million loss in the prior year period. Research and development expenses decreased to $34.4 million from $57.9 million, while selling, general and administrative expenses fell to $21.9 million from $26.4 million. The company ended the quarter with $307.8 million in cash and cash equivalents, up from $268.9 million at fiscal year-end, supported by proceeds from a common stock offering and debt drawdowns. Commercially, Replimune announced that TUDRIQEV is now available for use in combination with nivolumab to treat adults with advanced melanoma who have progressed on anti-PD-1 therapy, with more than 15 institutions having prescribed the treatment. The company operates as a commercial-stage biotechnology firm pioneering novel oncolytic immunotherapies.
